As set out in Virax Holdings Limited (Virax) (ASX:VHL)...

As set out in Virax Holdings Limited (Virax) (ASX:VHL) announcement to the market on 17 October 2014, Virax has entered into a binding agreement to acquire AKTivate Therapeutics Pty Ltd (ACN 168 507 202) (AKTivate).
Further to the notice of meeting released on 29 October 2014, the Company is seeking shareholder approval for the issue of 100,000,000 (on a pre-Consolidation basis) or 5,000,004 (on a post-Consolidation basis) ordinary shares to Paul Hopper, a director of the Company, and his associates (“Tranche 2 Shares”) in connection with the transaction to acquire 100% of the issued capital of AKTivate Therapeutics Pty Ltd. The Shareholders’ Meeting is being held on 28 November 2014.
Virax is pleased to announce that it has been granted a waiver by ASX in relation to ASX Listing Rule 10.13.3 to conditionally allow Virax to issue the Tranche 2 Shares outside of the period of 1 month after the date of the Shareholder’s Meeting (Waiver). The Waiver will allow Virax to issue:
(a) the Tranche 2 Shares no later than 24 months after the date of the shareholder approval at the annual general meeting, being no later than 28 November 2016.
The Waiver has been granted on the following further conditions:
(a) For any annual reporting period during which any of the Tranche 2 Shares have been issued or any of them remain to be issued, the Company’s annual report sets out in detail the basis on which the Tranche 2 Shares may be issued.
(b) In any half year or quarterly report for a period during which any of the Tranche 2 Shares have been issued or remain to be issued, the Company must include a summary statement of the number of Tranche 2 Shares issued during the reporting period, and the number of Tranche 2 Shares that remain to be issued.
(c) The Notice sets out in detail the milestones which must be satisfied prior to the issue of the Tranche 2 Shares.
(d) The milestones which must be satisfied for the Tranche 2 Shares to be issued are not varied.
(e) The Company releases the terms of the waiver to the market immediately